Oxbryta (Voxelotor) Mass Tort Case Leads
Connect with sickle cell disease patients and their families who suffered serious adverse events, including vaso-occlusive crisis, stroke, or death, from the recalled drug Oxbryta (voxelotor).
Oxbryta Sickle Cell Drug Litigation
Oxbryta (voxelotor), manufactured by Pfizer (formerly Global Blood Therapeutics), was approved to treat sickle cell disease in patients aged four and older. The FDA requested Pfizer voluntarily withdraw the drug from the market after post-marketing data revealed an imbalance of deaths and vaso-occlusive crises in patients taking Oxbryta compared to placebo. Lawsuits allege the manufacturer downplayed safety signals and continued marketing the drug despite evidence of serious harm.
Associated Conditions
- Vaso-occlusive crisis
- Death
- Stroke
- Acute chest syndrome
- Organ damage
- Worsening sickle cell complications
- Hospitalization for adverse drug events
Claimant Eligibility
- Prescribed and took Oxbryta (voxelotor) for sickle cell disease
- Experienced vaso-occlusive crisis, stroke, or other serious adverse event
- Hospitalized or required emergency treatment while on Oxbryta
- Family member of a patient who died while taking Oxbryta
- Medical records confirming Oxbryta prescription and adverse events
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Oxbryta legal marketing campaigns: how we acquire cases
Oxbryta case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Running a Oxbryta mass tort marketing campaign
Common questions from law firms about Oxbryta lawsuit lead generation and campaign management.
- What does a Oxbryta mass tort marketing campaign include?
- A Oxbryta mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Oxbryta case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Oxbryta mass tort case leads?
- Oxbryta mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Oxbryta legal marketing campaigns cost?
- Oxbryta legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Oxbryta leads exclusive to my firm?
- Yes. Every Oxbryta lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Oxbryta claimants qualified before delivery?
- Each Oxbryta claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Oxbryta case acquisition program scale?
- A Oxbryta mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
Get Oxbryta campaign pricing on a 30-minute call
We will walk your Oxbryta case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.